Close Menu

hepatitis

Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.

 

The company also announced deals for new DNA production and delivery technologies.

NEW YORK (GenomeWeb) – As Phase I testing of its hemophilia therapy ALN-AT3 continues, Alnylam Pharmaceuticals is setting its sights broadly for the program, taking aim at both patients receiving standard medical care as well as those who have become refractory to such treatment, company official

NEW YORK (GenomeWeb) – Just days after presenting Phase II data on its lead hepatitis B drug candidate that failed to meet Wall Street expectations and sent its stock into a tailspin, Arrowhead Research has been sued in two class action lawsuits alleging that the company misled investors as to wh

NEW YORK (GenomeWeb) – Shares of Arrowhead Research tumbled this week after the release of data from an ongoing Phase IIa trial of its siRNA-based hepatitis B drug ARC-520 showed unexpectedly modest reductions in HBV surface antigen (s-antigen), a key indicator of active infection.

NEW YORK (GenomeWeb) — Roche said today that it has received CE marking for the cobas 6800/8800 automated molecular testing systems for blood and plasma donor screening.

NEW YORK (GenomeWeb) – Mayo Medical Laboratories will collaborate with Advanced Biological Laboratories to develop a next-generation sequencing pipeline for laboratory-developed diagnostic tests.

NEW YORK (GenomeWeb) – As it continues to aim high with its investigational hepatitis B virus therapy ARC-520, Arrowhead Research this week announced that it has begun testing an even higher dose of the drug in patients in a single-dose Phase IIa trial.

NEW YORK (GenomeWeb) — Beckman Coulter Diagnostics said this month that it has received CE marking for Veris MDx, its "sample-in, results-out" real-time PCR-based molecular diagnostics system, as well as the platform's first assay, a quantitative viral load test for human cytomegalovirus.

Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.